Pharmaceutical Executive Europe - October 2008 - (Page 17)

Executive recruitment The expertise (level or type) required can alter daily, and an individual consultant does not have the experience/capability to deal with everything that crops up or easy access to others who do. ● A programme/project fails and a consultancy or interim contract ● still needs to be paid for in full. ● Contractors, who usually work in isolation, find it difficult to keep themselves up to date professionally and may not have all the skills required where an area of drug development has become highly specialized. Case studies A global pharmaceutical group widened its portfolio with a novel product through acquiring a biotech company. At the time, the product was in midlaunch for its primary indication as well as, being in a line-extension programme for another, ground-breaking indication. Faced with a lack of internal resources, and very limited expertise in the specific therapeutic area, the client’s medical, regulatory and marketing teams all required support in managing the regulatory submission and product launch. TranScrip provided medical and regulatory specialists, ensuring they integrated fully with the client team, resulting in successful registration of the new indication. They also provided constant support during the critical phase of the product launch. A biotech client, taking multiple programmes into clinical development, required a review and rebuild of the clinical and regulatory strategy documents, an analysis of the various logistic components and ongoing oversight of the programmes. Consequently, two very experienced drug developers did the initial review, with one continuing to provide intensive structural advice during the initial development phase of the programmes and, subsequently, on a reduced ad hoc basis. An experienced therapeutic area specialist medic was brought in to give regular medical oversight, and a regulatory specialist and programme leader were brought in to add their elements to the design and implementation. Stay more alert with Pharm Exec Europe Pharm Exec Europe online magazine is now publishing twice monthly e-Alerts, providing a variety of editorial for senior executives, corporate strategists & sales and marketing leaders in the European Pharmaceutical industry. E-Alerts will include ■ ■ Industry news ■ features ■ industry events commentaries ■ surveys ■ event information Join the readers who already receive the e-Alert by subscribing FREE now at www.pharmexeceurope.com and click on e-Alerts now! 19 Meet unmet needs Natalie Douglas on named patient programmes 22 Pharma in Turkey Interviews with the country’s leading executives 37 Last words Who said what in pharma’s last four weeks 3 News The monthly round-up of European stories http://www.pharmexeceurope.com http://www.pharmexeceurope.com

Table of Contents Feed for the Digital Edition of Pharmaceutical Executive Europe - October 2008

Pharmaceutical Executive Europe - October 2008 Contents News and Analysis Calendar BioFutures Strategy Fundamentals Executive Recruitment: Small Company, Big Career Executive Recruitment: Instant Pharma Named Patient Programmes Executive Review: Turkey

Pharmaceutical Executive Europe - October 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.